The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications

Bibliography

• Bole-Feysot C, Goffin V, Edery M, et al. Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 1998;19:225-68
   PubMed Web of Science ®Google Scholar
• Ormandy CJ, Camus A, Barra J, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167-78
   PubMed Web of Science ®Google Scholar
• Newey PJ, Gorvin CM, Cleland SJ, et al. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 2013;369:2012-20
   PubMed Web of Science ®Google Scholar
• Damiano JS, Wasserman E. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res 2013;19:1644-50
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27
   PubMed Web of Science ®Google Scholar
• Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005;26:400-22
   PubMed Web of Science ®Google Scholar
• Brooks CL. Molecular mechanisms of prolactin and its receptor. Endocr Rev 2012;33:504-25
   PubMed Web of Science ®Google Scholar
• Tallet E, Fernandez I, Zhang C, et al. Investigation of prolactin receptor activation and blockade using time-resolved fluorescence resonance energy transfer. Front Endocrin 2011;2:29
   Google Scholar
• Brooks A.J, Dai W, O’Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 2014;344:1249783
   PubMed Web of Science ®Google Scholar
• Marano RJ, Ben Jonathan N. Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol 2014;28:622-33
   PubMed Web of Science ®Google Scholar
• Newbern D, Freemark M. Placental hormones and the control of maternal metabolism and fetal growth. Curr Opin Endocrinol Diabetes Obes 2011;18:409-16
   PubMed Web of Science ®Google Scholar
• Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631
   PubMed Web of Science ®Google Scholar
• Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534
   PubMed Web of Science ®Google Scholar
• Ma FY, Anderson GM, Gunn TD, et al. Prolactin Specifically Activates STAT5b in Neuroendocrine Dopaminergic Neurons. Endocrinology 2005;146:5112-19
   PubMed Web of Science ®Google Scholar
• Goffin V, Kinet S, Ferrag F, et al. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 1996;271:16573-9
   PubMed Web of Science ®Google Scholar
• Bernichtein S, Kayser C, Dillner K, et al. Development of pure prolactin receptor antagonists. J Biol Chem 2003;278:35988-99
   PubMed Web of Science ®Google Scholar
• Goffin V, Tallet E, Jomain JB, Kelly PA. Development of Prolactin Receptor Antagonists: Same Goal, Different Ways. Rec Pat Endocr Metab Immune Drug Discov 2007;1:41-52
   Google Scholar
• Walker AM. S179D prolactin: antagonistic agony!. Mol Cell Endocrinol 2007;276:1-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Gong W, Breinholt J, et al. Discovery of the improved antagonistic prolactin variants by library screening. Protein Eng Des Sel 2011;24:855-60
   PubMed Web of Science ®Google Scholar
• Langenheim JF, Chen WY. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J Endocrinol 2009;203:375-87
   PubMed Web of Science ®Google Scholar
• Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23:623-46
   PubMed Web of Science ®Google Scholar
• Damiano JS, Rendahl KG, Karim C, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther 2013;12:295-305
   PubMed Web of Science ®Google Scholar
• Freiberg C, Otto C, Linden L, et al. Neutralizing prolactin receptor antibody mat3 and its therapeutic use. WO2012163932A1; 2012
   Google Scholar
• Jacobson EM, Hugo ER, Tuttle TR, et al. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab 2010;21:691-8
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Eliassen AH, Zhang X, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 2013;73:4810-19
   PubMed Web of Science ®Google Scholar
• Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011;165:209-15
   PubMed Web of Science ®Google Scholar
• Ferraris J, Bernichtein S, Pisera D, Goffin V. Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis. Neuroendocrinology 2013;98:171-9
   PubMed Web of Science ®Google Scholar
• Utama FE, Tran TH, Ryder A, et al. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 2009;150:1782-90
   PubMed Web of Science ®Google Scholar
• Nitze L.M, Galsgaard E.D, Din N, et al. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. Breast Cancer Res Treat 2013;142:31-44
   PubMed Web of Science ®Google Scholar
• Christensen HR, Murawsky MK, Horseman ND, et al. Completely humanizing prolactin rescues infertility in prolactin knockout mice and leads to human prolactin expression in extrapituitary mouse tissues. Endocrinology 2013;154(12):4777-89
   PubMed Web of Science ®Google Scholar
• Idelman G, Jacobson EM, Tuttle TR, Ben Jonathan N. Lactogens and estrogens in breast cancer chemoresistance. Expert Rev Endocrinol Metab 2011;6:411-22
   Google Scholar
• Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. J Mammary Gland Biol Neoplasia 2008;13:29-40
   PubMed Web of Science ®Google Scholar
• Peck AR, Witkiewicz AK, Liu C, et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011;29:2448-58
   Google Scholar
• Nouhi Z, Chughtai N, Hartley S, et al. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006;66:1824-32
   PubMed Web of Science ®Google Scholar
• Sultan AS, Xie J, LeBaron MJ, et al. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005;24:746-60
   PubMed Web of Science ®Google Scholar
• Barcus CE, Holt EC, Keely PJ, et al. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS One 2015;10:e0116891
   Google Scholar
• Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008;13:93-103
   PubMedGoogle Scholar
• Levina VV, Nolen B, Su Y, et al. Biological significance of prolactin in gynecologic cancers. Cancer Res 2009;69:5226-33
   PubMed Web of Science ®Google Scholar
• Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005;102:7677-82
   PubMed Web of Science ®Google Scholar
• Lopez-Pulido EI, Munoz-Valle JF, Toro-Arreola S, et al. High expression of prolactin receptor is associated with cell survival in cervical cancer cells. Cancer Cell Int 2013;13:103
   PubMed Web of Science ®Google Scholar
• Asai-Sato M, Nagashima Y, Miyagi E, et al. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int J Cancer 2005;115:539-44
   PubMed Web of Science ®Google Scholar
• Tan D, Chen KE, Khoo T, Walker AM. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. Cancer Lett 2011;310:101-8
   PubMed Web of Science ®Google Scholar
• Wen Y, Zand B, Ozpolat B, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 2014;7:488-500
   PubMed Web of Science ®Google Scholar
• Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005;10:325-35
   PubMed Web of Science ®Google Scholar
• Bogorad RL, Courtillot C, Mestayer C, et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA 2008;105:14533-8
   PubMed Web of Science ®Google Scholar
• Bilibio JP, Souza CA, Rodini GP, et al. Serum prolactin and CA-125 levels as biomarkers of peritoneal endometriosis. Gynecol Obstet Invest 2014;78:45-52
   PubMed Web of Science ®Google Scholar
• Martinez LB, Leyva MZ, Romero IC. Prolactin receptor in human endometriotic tissues. Acta Obstet Gynecol Scand 2002;81:5-10
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423
   PubMed Web of Science ®Google Scholar
• Stattin P, Rinaldi S, Stenman UH, et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer 2001;92:463-5
   PubMed Web of Science ®Google Scholar
• Sackmann-Sala L, Goffin V. Prolactin-induced prostate tumorigenesis. Adv Exp Med Biol 2015;846:221-42
   PubMed Web of Science ®Google Scholar
• Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 2002;143:228-38
   PubMed Web of Science ®Google Scholar
• Tan SH, Dagvadorj A, Shen F, et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008;68:236-48
   PubMed Web of Science ®Google Scholar
• Thomas LN, Morehouse TJ, Too CK. Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Prostate 2012;72:450-60
   PubMed Web of Science ®Google Scholar
• Thomas LN, Merrimen J, Bell DG, et al. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting. Prostate 2014;74:732-42
   PubMed Web of Science ®Google Scholar
• Rouet V, Bogorad RL, Kayser C, et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci USA 2010;107:15199-204
   PubMed Web of Science ®Google Scholar
• Sackmann-Sala L, Chiche A, Mosquera-Garrote N, et al. Prolactin-induced prostate tumorigenesis links sustained stat5 signaling with the amplification of basal/stem cells and emergence of putative luminal progenitors. Am J Pathol 2014;184:3105-19
   PubMed Web of Science ®Google Scholar
• Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science 2010;329:568-71
   PubMed Web of Science ®Google Scholar
• Kindblom J, Dillner K, Ling C, et al. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 2002;53:24-33
   PubMed Web of Science ®Google Scholar
• Van Coppenolle F, Slomianny C, Carpentier F, et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001;280:E120-9
   PubMed Web of Science ®Google Scholar
• Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410-15
   PubMed Web of Science ®Google Scholar
• Kindblom J, Dillner K, Sahlin L, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003;144:2269-78
   PubMed Web of Science ®Google Scholar
• Bernichtein S, Pigat N, Camparo P, et al. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate 2015;75:706-22
   PubMed Web of Science ®Google Scholar
• Lai KP, Huang CK, Fang LY, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol 2013;27:1617-31
   PubMed Web of Science ®Google Scholar
• Syms AJ, Harper ME, Griffiths K. The effect of prolactin on human BPH epithelial cell proliferation. Prostate 1985;6:145-53
   PubMed Web of Science ®Google Scholar
• Leav I, Merk FB, Lee KF, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999;154:863-70
   PubMed Web of Science ®Google Scholar
• Galsgaard ED, Rasmussen BB, Folkesson CG, et al. Re-evaluation of the prolactin receptor expression in human breast cancer. J Endocrinol 2009;201:115-28
   PubMed Web of Science ®Google Scholar
• Rannikko S, Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983;4:223-9
   PubMed Web of Science ®Google Scholar
• Colao A, Vitale G, Di Sarno A, et al. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 2004;89:2770-5
   PubMed Web of Science ®Google Scholar
• McPherson SJ, Wang H, Jones ME, et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001;142:2458-67
   PubMed Web of Science ®Google Scholar
• Yatkin E, Bernoulli J, Talvitie EM, Santti R. Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int J Androl 2009;32:399-410
   PubMed Web of Science ®Google Scholar
• Lobie PE, Garcia-Aragon J, Waters MJ. Prolactin receptor expression in the gastrointestinal tract: characterization of the prolactin receptor of gastric mucosa. J Endocrinol 1993;139:371-82
   PubMed Web of Science ®Google Scholar
• Nagano M, Chastre E, Choquet A, et al. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol 1995;268:G431-42
   PubMed Web of Science ®Google Scholar
• Bhatavdekar JM, Patel DD, Vora HH, et al. Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience. Head Neck 2000;22:257-64
   PubMed Web of Science ®Google Scholar
• Chauhan A, Kurian J, Kakria A, et al. Prognostic value of prolactin in postoperative colorectal carcinoma. Gastrointest Cancer Res 2008;2:260-1
   PubMedGoogle Scholar
• Neradugomma NK, Subramaniam D, Tawfik O, et al. Prolactin induces Notch signaling in a Jak2-STAT and Jak2-ERK pathways in colon cancer stem and progenitor cells. Carcinogenesis 2013;35:795-806
   PubMedGoogle Scholar
• Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci 1996;59:599-614
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol 1998;157:187-97
   PubMed Web of Science ®Google Scholar
• Kooijman R, Gerlo S, Coppens A, Hooghe-Peters EL. Myeloid leukemic cells express and secrete bioactive pituitary-sized 23 kDa prolactin. J Neuroimmunol 2000;110:252-8
   PubMed Web of Science ®Google Scholar
• Langan EA, Foitzik-Lau K, Goffin V, et al. Prolactin: an emerging force along the cutaneous-endocrine axis. Trends Endocrinol Metab 2010;21:569-77
   PubMed Web of Science ®Google Scholar
• Ramot Y, Biro T, Tiede S, et al. Prolactin--a novel neuroendocrine regulator of human keratin expression in situ. FASEB J 2010;24:1768-79
   PubMed Web of Science ®Google Scholar
• Goldstein J, Fletcher S, Roth E, et al. Calcineurin/Nfatc1 signaling links skin stem cell quiescence to hormonal signaling during pregnancy and lactation. Genes Dev 2014;28:983-94
   PubMed Web of Science ®Google Scholar
• Langan EA, Ramot Y, Goffin V, et al. Mind the (gender) gap: does prolactin exert gender and/or site-specific effects on the human hair follicle? J Invest Dermatol 2010;130:886-91
   PubMed Web of Science ®Google Scholar
• Foitzik K, Krause K, Conrad F, et al. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol 2006;168:748-56
   PubMed Web of Science ®Google Scholar
• Lutz G. Hair loss and hyperprolactinemia in women. Dermatoendocrinology 2012;4:65-71
   PubMedGoogle Scholar
• Lapointe TK, Altier C. The role of TRPA1 in visceral inflammation and pain. Channels (Austin) 2011;5:525-9
   PubMed Web of Science ®Google Scholar
• Vriens J, Appendino G, Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009;75:1262-79
   Google Scholar
• Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 1972;35:840-51
   PubMed Web of Science ®Google Scholar
• Patil MJ, Green DP, Henry MA, Akopian AN. Sex-dependent roles of prolactin and prolactin receptor in postoperative pain and hyperalgesia in mice. Neuroscience 2013;253:132-41
   PubMed Web of Science ®Google Scholar
• Bosco D, Belfiore A, Fava A, et al. Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. J Headache Pain 2008;9:103-7
   PubMed Web of Science ®Google Scholar
• Dev R, Hui D, Dalal S, et al. Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer. J Pain Symptom Manage 2011;41:788-95
   PubMed Web of Science ®Google Scholar
• Patil MJ, Ruparel SB, Henry MA, Akopian AN. Prolactin regulates TRPV1, TRPA1, and TRPM8 in sensory neurons in a sex-dependent manner: Contribution of prolactin receptor to inflammatory pain. Am J Physiol Endocrinol Metab 2013;305:E1154-64
   PubMed Web of Science ®Google Scholar
• Scotland PE, Patil M, Belugin S, et al. Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia. Eur J Neurosci 2011;34:745-54
   PubMed Web of Science ®Google Scholar
• Diogenes A, Patwardhan AM, Jeske NA, et al. Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. J Neurosci 2006;26:8126-36
   PubMed Web of Science ®Google Scholar
• Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012;11:A465-70
   PubMed Web of Science ®Google Scholar
• Dillner K, Kindblom J, Flores-Morales A, et al. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 2003;144:4955-66
   PubMed Web of Science ®Google Scholar
• Orbach H, Zandman-Goddard G, Boaz M, et al. Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients. Clin Rev Allergy Immunol 2012;42:189-98
   PubMed Web of Science ®Google Scholar
• Stevens A, Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene--implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 2001;10:676-83
   PubMed Web of Science ®Google Scholar
• Mellai M, Giordano M, D’Alfonso S, et al. Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Hum Immunol 2003;64:274-84
   PubMed Web of Science ®Google Scholar
• Leanos-Miranda A, Cardenas-Mondragon G, Rivera-Leanos R, et al. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. Clin Endocrinol (Oxf) 2006;65:146-53
   PubMed Web of Science ®Google Scholar
• Langan EA, Griffiths CE, Paus R. Exploring the role of prolactin in psoriasis. Arch Dermatol Res 2012;304:115-18
   PubMed Web of Science ®Google Scholar
• Reuwer AQ, Hoekstra M, Touraine P, et al. Is prolactin involved in the evolution of atherothrombic disease? Expert Rev Endocrinol Metab 2012;7:345-61
   PubMedGoogle Scholar
• van der Sluis RJ, van den AT, Reuwer AQ, et al. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility. J Endocrinol 2014;222:341-50
   PubMed Web of Science ®Google Scholar
• El Chemaly S, Henske EP. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014;23:30-5
   PubMedGoogle Scholar
• Terasaki Y, Yahiro K, Pacheco-Rodriguez G, et al. Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2010;182:531-9
   PubMed Web of Science ®Google Scholar
• Sanati S, Watson MA, Salavaggione AL, Humphrey PA. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol 2009;22:1273-9
   PubMed Web of Science ®Google Scholar
• Broughton SE, Hercus TR, Lopez AF, Parker MW. Cytokine receptor activation at the cell surface. Curr Opin Struct Biol 2012;22:350-9
   PubMed Web of Science ®Google Scholar
• Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol 2011;8:597-607
   PubMed Web of Science ®Google Scholar